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Abstract.
Cancer progresses with a change in the structure of the gene network in normal
cells. We define a measure of organizational hierarchy in gene networks of affected
cells in adult acute myeloid leukemia (AML) patients. With a retrospective cohort
analysis based on the gene expression profiles of 116 acute myeloid leukemia
patients, we find that the likelihood of future cancer relapse and the level of
clinical risk are directly correlated with the level of organization in the cancer
related gene network. We also explore the variation of the level of organization
in the gene network with cancer progression. We find that this variation is non-
monotonic, which implies the fitness landscape in the evolution of AML cancer cells
is nontrivial. We further find that the hierarchy in gene expression at the time of
diagnosis may be a useful biomarker in AML prognosis.
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1. Introduction
Cancer cells break the most basic rules of cell behavior by which multicellular
organisms are built and maintained, and they exploit every kind of opportunity
to do so [1]. They proliferate without restraint and prosper at the expense of
their neighbors in a multicellular environment. The development of cancer typically
requires that a substantial number of independent, rare genetic and epigenetic
accidents occur in the lineage of one cell. Cancer, therefore, involves changes in
the pattern of gene expression in normal cells. It involves disruption in the normal
mechanisms of gene control and regulation, which results in correlated gene networks
in a cell going astray. Since cancer progresses with changes in the gene network, the
structure of the gene network in cancer cells may be predictive of clinical risk and
outcome [2–10].
Acute myeloid leukemia (AML) is the most common acute leukemia in adults.
Chemotherapy induces a complete remission in 70 to 80 percent of patients aged 16
to 60 years, but many of them have a relapse and die of their disease. Myeloablative
conditioning followed by allogeneic stem-cell transplantation can prevent relapse,
but this approach is associated with a high treatment-related mortality. Therefore,
accurate predictors of the clinical outcome are needed to determine appropriate
treatment for individual patients [11, 12]. Currently used prognostic indicators
include age, cytogenetic findings, the white-cell count, and the presence or absence
of an antecedent hematologic disorder [13].
Cancer is a microevolutionary process. We are motivated to study the
hierarchical structure in cancer affected cells by a theory that relates development of
hierarchy during evolution to environmental stress and variability [14–17]. According
to this theory, during evolution in a rugged fitness landscape amidst a changing
environment a system tends to become more hierarchical, since hierarchy tends to
increase the adaptability of the system. Therefore, we expect more aggressive cancer
cells to exhibit a higher level of hierarchical organization in their cancer related gene
network. Cancers with a more hierarchical cancer related gene network are expected
to be more adaptable and competitive, and thus have a higher chance of relapsing.
We here provide support for this theory in the case of AML.
Structure in gene networks in cancer cells has been quantified, and it has
been found to be useful in cancer prognosis. Vineetha et al. applied a TSK-type
recurrent neural fuzzy approach to extract regulatory relationship among genes and
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to reconstruct gene regulatory network from microarray data from colon cancer
cells. Structure in this regulatory network provided new insights into colon cancer
diagnostics [18]. Taylor et al. used the co-expression of hub proteins and their
partners to identify whether interactions are context-specific, or constitutive. They
found that loss of co-regulation in cancer results in disruptions in hub protein
components of interaction networks [2, 3]. Ford et al. used gene expression microarray
data to predict the recurrence time in lung cancer [19].
Hierarchy is a measure of modularity that exists in gene expression networks at
different levels. Here, we quantify the hierarchy in cancer related gene networks and
explore its relation with clinical risk and outcome in AML. That is, we study the
relation between cancer relapse and the structural features of the gene network in
cancer affected cells. We will show that the level of organization and hierarchy in
the cancer related gene network in AML affected cells can serve as a biomarker in
AML prognosis. There is a significant difference in the hierarchy measure between
patients that have a cancer relapse (34 patients) and those that do not (43 patients)
(p-value=0.0012). The area under the ROC curve for the classifier that discriminates
between the relapse and no relapse patient cohorts on the basis of the hierarchy
measure is 0.70, which is significant compared to a random classifier.
2. Methods
2.1. Patients
We performed a retrospective cohort analysis based on the gene expression profiles
of acute myeloid leukemia patients (samples provided by the AML Study Group,
Ulm, Germany). The gene expression data were previously obtained from samples
obtained from 116 AML patients (median age, 50 years) [11]. Of the various genes
analyzed, 133 genes predictive of clinical outcome were identified [11]. Relapse in
patients was monitored during the follow up visits. Subsequent reports, working
with other datasets, have also reported gene expression data in AML associated
with prognosis [20–22].
During the follow up period, 68 of the 116 patients died, and 34 of the 79
patients who had complete remission relapsed. 20 patients were also reported to
have developed a refractory cancer disease. For the patients who died during the
follow up period, the overall survival since diagnosis was also reported.
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2.2. Cytogenetics
Cytogenetic analysis can be used to classify AML patients as being at low risk
[t(8;21), t(15;17), or inv(16)], intermediate risk [e.g., a normal karyotype or t(9;11)],
or high risk [e.g., inv(3), -5/del(5q), -7, or a complex karyotype (three or more
aberrations)] [23–25]. We categorized the patients into these categories depending
on the cytogenetic aberration reported for each patient [11].
2.3. Gene networks for different patient categories
To study the structure and organization of the gene network in different patient
groups, we defined a network consisting of 133 genes previously identified as being
predictive of clinical outcome in AML [11] as nodes. The weight of the link between
any two nodes was defined using the Pearson correlation coefficient as
lα,β =
n∑
i
(Pi,α − µα)(Pi,β − µβ)
σασβ
(1)
Here Pi,α is the expression data of gene α for patient i from [11], µα is the average
expression value for gene α for the n patients, and σα is the standard deviation of
expression value of gene α for the n patients. Using the above definition, we make
comparisons between the following sets of categories of patients:
2.3.1. Relapse, remission with no relapse, and refractory disease groups In order to
make comparisons between these groups that contain a different number of patients
each, we chose 16 patients randomly from each group and constructed the gene
network. This random selection of patients from each category helps to mitigate
the bias due to different group sizes. We repeated this procedure 100 times which
gave us 100 networks for each group. Error bars were calculated using this bootstrap
procedure. Representative networks are shown in Figure 1.
2.3.2. Low, intermediate, and high risk groups The karyotype was used to classify
AML patients into low risk, intermediate risk, or high risk categories depending
on the cytogenetic aberration reported for each patient [11]. We thus had three
categories of patients: low risk group consisting of 38 patients, intermediate risk
group consisting of 57 patients, and high risk group consisting of 16 patients. To
make comparisons between these groups that contain a different number of patients
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Figure 1: Shown are representative gene expression networks for a) complete remission,
b) refractory disease, and c) relapse. The nodes are the 133 cancer related genes and the
links are calculated from Eq. (1) from one group of 16 patients from each of the three
patient categories. The CCC values are CCCremission = 0.2270 < CCCrefractory = 0.2601 <
CCCrelapse = 0.5140.
each, we randomly chose 12 patients from each category and constructed the cancer
related gene network. We repeated this procedure 100 times to mitigate any bias
due to unequal sample sizes. This gave us 100 networks for each risk category. We
calculated error bars using this bootstrap procedure.
2.3.3. Groups with cancer at different levels of progression 68 of the 116 patients
died during the follow up period. The overall survival since diagnosis had been
reported for each of these patients [11]. We sorted the survival time dataset in
descending order and divided it into 6 groups, each consisting of 16.67% of the
dataset. Samples were assigned into groups (sextiles) based on length of survival
from initial cancer diagnosis. We constructed the gene network for each of these
groups as stated above using Eq. (1) to define links between nodes.
2.4. Gene network for each patient
We constructed a network with 133 cancer related genes as nodes for each patient in
our dataset. Two different methods were used to define the weights of the links in
the network.
2.4.1. Deviation of gene expression from average expression profile of AML cells
We defined the weight of the link between any two nodes i and j in the network for
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patient α as follows:
lαi,j =
116∑
k=1
|X ik −X
j
k| (2)
where X ik = (expression of gene i in patient k - expression of gene i in patient α)
2, i.e.
the deviation of gene expression i for patient α from the average in the entire cancer
dataset [11]. We will show that the structure of such a network can discriminate
between the patients that have cancer relapse and those that do not.
2.4.2. Deviation of gene expression from average expression in different normal
human tissues We used the gene expression data previously collected from 79
normal human tissues [26]. Cancer cells exhibit a gene expression profile different
from cells in normal human tissues due to various mutations. We were motivated
to study the deviations from normal expression profiles in different patients and the
level of organization in these deviations. We, therefore, constructed a network with
133 cancer related genes as nodes and defined the weight of a link between nodes i
and j as follows:
lαi,j =
79∑
k=1
X ik ∗X
j
k (3)
where X ik = (average expression of gene i in normal tissue k - expression of gene i
in cancer cells in patient α)2, i.e. the deviation of expression of gene i in patient α
from the average expression of gene i in normal human tissues [26].
2.5. The CCC
To quantify the structure in these gene networks, we defined a measure of hierarchy
that quantifies how “tree-like” a network is [27]. The motivation behind this is
that a tree network topology is the typical hierarchical structure. To calculate this
measure, we computed the distance matrix defined by the network. The distance
between nodes i and j, di,j, is defined by the square root of the commute time. The
commute time is the expected time taken by a random walker to travel from one
of the nodes to the other and back to the starting node [28]. Besides the weight of
the link between the nodes i and j, the commute time between nodes i and j also
depends on all possible paths between the two nodes in the graph. In a weighted
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graph, the commute time between two nodes decreases with an increase in the number
of possible paths from one node to the other and increases with an increase in the
length of any path connecting the two nodes. Due to these properties, the commute
time is well suited for clustering tasks. To define the commute time, we let L denote
the graph Laplacian, defined as L = D−A, where A is the matrix of links, A = l in
Eq. (1), (2) or (3), and the diagonal matrix D = diag(Ai), with Ai =
∑
j Aij. The
commute time is obtained using L+, the Moore-Penrose pseudoinverse of the graph
Laplacian L by [29]
n(i, j) = VG(ei − ej)
TL+(ei − ej). (4)
Here (ei)j = δij , and VG =
∑
ij aij . Since L+ is symmetric and positive semidefinite,
dij =
√
n(i, j) is a Euclidean distance metric, called the Euclidean commute time
(ECT) distance.
To construct a tree topology that best approximates our original network, we
applied the average linkage hierarchical clustering algorithm [30]. This method takes
the distance matrix defined by the gene network and produces a tree topology that
best reproduces the original distances. The tree topology has the same nodes as the
original network but different weights for the links between nodes. We calculated
the correlation between the distances between all pairs of nodes in the original
network and the distances between these pairs in the best-fitting tree. This gives the
cophenetic correlation coefficient (CCC). The higher the correlation, the better does
the tree topology approximate the original network and, thus, the more hierarchical
is the original network. The best fitting tree to the distance metric data defines an
approximation to the original network, termed the cophenetic matrix. The element
cij of the cophenetic matrix is the height where the network nodes i and j become
members of the same cluster in the tree. It defines the distance between the nodes i
and j. The CCC is defined as
CCC =
∑
i<j(dij − d)(cij − c)√
(
∑
i<j(dij − d)
2
∑
i<j(cij − c)
2
(5)
Here d is the average of the distances in the original network, dij, and c is the average
of the tree distances, cij.
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Figure 2: a) The mean normalized CCC of the cancer related gene network for the three
categories of patients: patients that have a complete remission with no relapse during the
follow up, patients that have a refractory disease, and patients that have a cancer relapse
during the follow up. The links between nodes were calculated using Eq. (1). b) The mean
normalized CCC of the cancer related gene network for different risk groups: low risk,
intermediate risk, and high risk. The links between nodes were calculated using Eq. (1).
Error bars are one standard error.
3. Results
3.1. Clinical outcome groups
We constructed networks comprising of 133 cancer related genes as nodes and
the links calculated using Eq. (1) for each out of the three outcome categories:
relapse, refractory disease, and complete remission with no relapse during follow
up. Figure 2a shows the results. We compared these CCC values with those
from a random network with the same number of nodes and edges as the cancer
related gene networks. We built 100 such random networks with redistributed
link values. We defined a normalized cophenetic correlation coefficient as follows:
CCCnorm = (CCC −CCCrand)/(1−CCCrand) where CCCrand is the average CCC
for a random network of the same size. Normalized CCC values are shown in Figure
2a. We computed the z-scores of the cancer-associated network CCC relative to
the distribution of the CCC values of the random networks of the same size and
sparsity: ZCCC = (CCC−CCCrand)/σrand . The z-scores for remission (no relapse),
refractory disease, and relapse are 1.76, 2.84, and 4.05, respectively. The difference
between remission and relapse groups is significant for a Student’s t-test with a
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Figure 3: The mean normalized CCC in the cancer related gene network for patients
in different sextiles of survival time from initial diagnosis. The hierarchy in the network
increases, peaking in the intermediate sextiles of survival time.
p-value < 0.001.
3.2. Risk groups
Figure 2b shows the normalized CCC values for the three categories calculated as
before. The high risk category has the maximum hierarchy among the three groups
followed by intermediate, and low risk groups. The z-scores for low, intermediate,
and high risk groups are 2.45, 3.67, and 3.90, respectively.
3.3. Cancer Progression
We again constructed the cancer related gene network for patients exhibiting different
sextiles of survival time and calculated the average normalized CCC and standard
error in this average. The results are as shown in Figure 3 wherein the independent
axis indicates the time period between AML diagnosis and death, which we interpret
as a measure of cancer progression, and the dependent axis indicates the mean
normalized CCC. We observe that the variation of mean CCC with increasing levels
of cancer progression is non-monotonic. This result makes manifest the non-trivial
changes that occur in the cancer related gene expression network as a function of
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remaining survival time.
3.4. Gene network for individual patients
We constructed a cancer related gene network for each of the 116 patients with 133
cancer related genes as nodes and links defined in two different ways:
3.4.1. Deviation of cancer cells gene expression from average expression profile of
AML cells The links between nodes were calculated using Eq. (2). The distribution
of CCC values for relapse, remission, and refractory disease are shown in Figure 4.
The difference between patients exhibiting relapse and those exhibiting complete
remission is statistically significant for a Student’s t-test with a p-value of 0.0019.
We plot a ROC curve for the prediction that patients with CCC > cutoff have a
relapse. The area under the ROC curve (AUC) is 0.67 which is significant compared
to a random classifier.
3.4.2. Deviation of cancer cells gene expression from average expression in different
healthy human tissues The links between nodes are calculated using Eq. (3).
The difference between patients exhibiting relapse and those exhibiting complete
remission is significant with a p-value of 0.0012. We plot a ROC curve for the
prediction that patients with CCC > cutoff have a relapse, shown in Figure 5a. The
area under the ROC curve (AUC) is 0.70 which is significant compared to a random
classifier.
We further used the CCC values for individual patient gene networks to predict
the risk of death within 3 years of cancer diagnosis. For this purpose, we used the
cancer related gene network for each patient with links calculated using Eq. (2). We
calculated the CCC values for 68 patients who died during the follow up period and
for the patients who were alive at the end of follow up. The difference between the
two categories is statistically significant for a Student’s t-test with a p-value < 0.001.
Using these CCC values for the two groups, we attempted to predict the chances
of death within 3 years of cancer diagnosis by setting a cutoff on the CCC values.
The AUC of the ROC curve for this prediction is 0.69 which is again significant as
compared to a random classifier.
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Figure 4: The Gaussian distribution fit to CCC values for the patients in different clinical
outcome categories: patients that have a complete remission with no relapse during the
follow up (solid), patients that have a refractory disease (dotted), and patients that have
a cancer relapse during the follow up (dashed). We constructed a cancer related gene
network for each patient in the dataset with 133 cancer related genes as nodes and links
calculated using Eq. (1).
4. Discussion
There are selection pressures on a tumor that are distinct from those upon the host.
The proliferation and progression of cancer involves activation of cancer-specific gene
pathways, perhaps hijacked ancestral host pathways [31]. Thus, in contrast to the
classical view of cancer as a dedifferentiation of the host, progression of a tumor
may involve structuring of specific expression pathways. For example, we have here
suggested that a more aggressive and resistant cancer is expected to have a more
structurally organized and modular cancer-associated network. This is, indeed,
observed in Figure 2a. The average CCC is the highest for patients that exhibit
a cancer relapse during the follow up. Post remission, there is competition between
the residual cancerous cells and the normal or transplanted stem cells in the bone
marrow. To compete against and to drive out these cells, there is selection for a more
organized and modular cancer related genes network among the AML cells. Hence,
we expected higher hierarchy in the gene network for patients that exhibit cancer
Hierarchy in Gene Expression is Predictive for Adult Acute Myeloid Leukemia 12
a)
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
False Positive Rate
Tr
ue
 P
os
iti
ve
 R
at
e
b)
0 200 400 600 800 1000 1200 1400
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Number of days since diagnosis
Em
pi
ric
al
 p
ro
ba
bi
lity
 o
f s
ur
viv
al
 
 
CCC > cutoff
CCC < cutoff
Figure 5: a) The receiver operating characteristic (ROC) curve for the prediction that
CCC > cutoff leads to future relapse. The CCC is calculated for the cancer related gene
network with links calculated using Eq. (2). The area under the curve(AUC) is 0.70 which
is significant as compared to a random classifier. b) The probability of survival for patients
with CCC > cutoff (dashed) and patients with CCC < cutoff (solid). For patients alive at
the end of follow up (n = 48), survival time represents the number of days to last follow up.
The hazard ratio is 2.04. Thus, higher CCC implies lower chances of survival as compared
to patients with lower CCC in the cancer related gene network. Here, cutoff = mean CCC
for all 116 patients.
relapse during follow up. For patients that exhibit complete cancer remission and
no relapse, the average CCC is the lowest. In these patients, the cancer cells are
completely eradicated during chemotherapy. Any residual cells in the bone marrow,
if present, are unable to compete against the normal stem cells and are unable to start
proliferating again aggressively enough for cancer to relapse. Therefore, we expected
cancer cells in these patients to exhibit the lowest level of organization in the cancer
related genes network. In some AML cases, the cancer cells evolve mechanisms to
resist the entry of anti-cancer chemo drugs into the cells. These cancers are thus
resistant to existing chemotherapy procedures, and such patients are said to have
a refractory cancer disease. In such cases, there is less selection pressure on AML
cells since these are already resistant to anti-cancer drugs. Hence, we expected the
cancer related gene network in such patients to be less organized as compared to
patients that exhibit relapse. On the other hand, since these cancer cells are drug
resistant and also compete with the normal bone marrow cells, they exhibit a higher
level of organization as compared to cancer cells from patients exhibiting complete
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remission.
Cancers exhibiting a higher level of organizational hierarchy and modularity in
the cancer related genes network are expected to be more competitive, proliferative,
and aggressive and, thus, present a higher level of risk for the host. This is, indeed,
observed in Figure 2b wherein the average CCC increases with increasing risk. Here,
the different risk categories were determined depending of the cytogenetic profile of
the patients [11, 23–25].
We also calculated the average CCC of the cancer related gene network for
patients as a function of survival time since initial cancer diagnosis. The results are
shown in Figure 3. As cancer progresses, cancer cells compete with the host cells for
oxygen and nutrition. The host immune system attempts to resist or eradicate tumor
progression [32–35]. Cancer cells thus evolve in a rugged fitness landscape. Therefore,
there is selection for more effective, aggressive, and proliferative gene pathways since
cancer cells evolve amidst tremendous environmental pressure from the host cells and
the host immune system [36]. During evolution in such a rugged fitness landscape,
theory shows that modularity in gene networks is selected for [14, 15]. Therefore,
the cancer related gene network becomes more organized and modular as cancer
progresses and matures. However, once the cancer reaches a mature phase, the host
immune system is severely compromised, especially in the cancer microenvironment
[37, 38]. Also, cancer cells now dominate the tissue environment with their high
proliferation rates, induced angiogenesis and reprogrammed energy metabolism [39].
Therefore, there is less selection pressure since the cancer cells do not have to compete
as much with the host marrow cells or the impaired and compromised immune
system. This presents a relatively smooth fitness landscape for cancer cell evolution
with little or no selection, and theory shows that modularity is selected for less
strongly [14, 15]. Thus, we expect the level of organization of the cancer associated
gene network to decline once the cancer has dominated the host. That is, we suggest
that the level of organization in the cancer related gene networks declines due to
less selection pressure requiring this costly structure in the advanced phase of the
cancer. Modifications to the expression network of the cancer associated genes may
stem from mutations, compromised DNA replication, or other mechanisms in cancer
cells [40]. We suggest that nonmonotonic selection pressure may be the reason for
the nonmonotonic variation of modularity with cancer progression seen in Figure 3.
We also attempted to differentiate between patients that exhibit relapse during
follow up from patients that do not show any relapse using the level of organization
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in cancer related gene network in their cancerous cells at the time of diagnosis. For
this, we constructed a cancer related gene network for each patient with 133 cancer
related genes as nodes and links defined with either Eq. (2) or (3). We then set a
cutoff on the CCC values to discriminate between patients with relapse and non-
relapse cases. The area under the ROC curve is 0.69 and 0.70, respectively, for the
two cases which is significant as compared to a random classifier. We also constructed
a cancer related gene network for each patient using Eq. (3), considering deviation
of gene expression in cancer cells from normal, non-cancerous, healthy bone marrow,
and myeloid blood cells only. When classifying using CCC values calculated from
these networks, the area under the ROC curve (not shown) was 0.65. Similarly, we
attempted to predict the chances of death for a patient within 3 years of diagnosis
using the CCC value of the cancer related gene network at the time of diagnosis.
We again set a cutoff on the CCC values to discriminate between patients who died
during the follow up from patients that were alive at the end of follow up. The AUC
is 0.69 which is again statistically significant in comparison with a random classifier.
The CCC of the cancer related gene network in the cancerous cells of a patient is
a biomarker in AML prognosis. It is discriminating and may help identify patients
that are at a higher risk of a relapse after a typical chemotherapy regime before the
treatment has begun. This biomarker may also help to identify the overall risk that
the patient is subject to, which may be helpful in deciding upon a chemotherapy
regime for each patient.
5. Conclusion
We defined a measure of hierarchical organization in gene pathways in AML cancer
cells. With a retrospective cohort analysis based on the gene expression profiles of 116
acute myeloid leukemia patients, we found that the level of organization, indicated
by CCC values, correlates with the clinical outcome in AML and with the level of
risk the cancer presents for the host. It also correlates with the survival period in the
case of dead patients. We expected this result since a more organized and modular
network of cancer associated genes is likely to contribute towards a more aggressive
form of cancer. Further, since cancer cells evolve in a rugged fitness landscape, a
more organized cancer related gene network will be selected for amidst the immense
selection pressure in a changing, hostile environment [1, 14, 15]. We also showed
how the level of organization in cancer associated gene pathways varies as cancer
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progresses and matures. This variation is non-monotonic, likely due to a decrease
in the selection pressure once the cancer dominates. Finally, the CCC calculated
for each patient can serve as a biomarker in AML prognosis to assess the risk of
relapse and overall risk level for a patient and thus to inform a suitable personalized
treatment regime.
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